ROP drug granted orphan designation

Article

Iplex (mecasermin rinfabate), a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3) developed for the treatment of retinopathy of prematurity (ROP), has been granted orphan drug designation by the EMEA, according to a statement from Iplex developers Insmed Inc and Premacure AB.

Iplex (mecasermin rinfabate), a complex of recombinant human insulin-like growth factor-I (rhIGF-I) and its predominant binding protein IGFBP-3 (rhIGFBP-3) developed for the treatment of retinopathy of prematurity (ROP), has been granted orphan drug designation by the EMEA, according to a statement from Iplex developers Insmed Inc and Premacure AB.

The orphan designation entitles Premacure to assistance and reduced fees for pre- and post-authorization activities.

Iplex is currently approved in the US for the treatment of growth failure in children. Premacure intends to launch a multicentre Phase II trial of Iplex in the ROP indication during the second quarter of this year, and to continue investigating the drug for other indications.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
A group of older elderly people exercise outdoors. Concept image for dry eye disease and aging, demographics of Tear Film and Ocular Surface Society TFOS DEWS III Digest report. Image credit: ©Rido – stock.adobe.com

Interdisciplinary report illuminates demographic, systemic health factors of dry eye disease

Jordana Joy
July 2nd 2025
Article

Remaining questions about DED pertain to geographic considerations, prevalence measures for DED in children and the design of future studies to determine risk factors in patients under 40

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A person's hands are visible as they search in a file cabinet. Concept image for new categorisation of intraocular lens. Image credit: ©Stephen Coburn – stock.adobe.com

How a newly defined category of IOLs can benefit patient outcomes

Joaquín Fernández Pérez, MD, PhD, MSc
June 30th 2025
Article

A new functional classification can help achieve precise vision goals

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME

Iridex enrolls first patient in study evaluating MicroPulse technology as an adjunct to anti-VEGF therapy for DME

Martin David Harp
June 26th 2025
Article

The study will be led by principal investigator professor Noemi Lois, MD, PhD, FRCS(Ed), FRCOphth, at Queen’s University Belfast, in over 20 clinical sites, and plans to enroll 264 patients across the UK with severe DME.

From left, clockwise: scans of a patient's left and right eyes; a photo of article author Johann Krüger, MD; Dr Krüger's handwritten notes from a custom match IOL implantation

Custom matching IOLs is key to managing patient satisfaction

Johann Krüger, MD
June 26th 2025
Article

Johann Krüger, MD, shares insights from 26 years of experience

© 2025 MJH Life Sciences

All rights reserved.